Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.04 HKD | +1.29% | +3.68% | +5.39% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.39% | 620M | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- China Accepts New Drug Application for Ocumension Therapeutics' Anti-Allergy Eye Drops